MX357746B - Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. - Google Patents
Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma.Info
- Publication number
- MX357746B MX357746B MX2013002668A MX2013002668A MX357746B MX 357746 B MX357746 B MX 357746B MX 2013002668 A MX2013002668 A MX 2013002668A MX 2013002668 A MX2013002668 A MX 2013002668A MX 357746 B MX357746 B MX 357746B
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- subject
- syngeneic
- graft
- central memory
- Prior art date
Links
- 210000003071 memory t lymphocyte Anatomy 0.000 title abstract 2
- 206010025323 Lymphomas Diseases 0.000 title 1
- 230000000719 anti-leukaemic effect Effects 0.000 title 1
- 230000000690 anti-lymphoma Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 230000001939 inductive effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para tratar una enfermedad en un sujeto en necesidad del mismo. El método que comprende: (a) trasplantar una célula o injerto de tejido no singeneico al sujeto; y (b) administrar al sujeto una cantidad terapéuticamente efectiva de una población aislada de células que comprenden células anti-tercera parte que inducen no injerto contra hospedero (GVHD) que tienen un fenotipo de T-linfocito de memoria central (Tcm), las células que son células inductoras de tolerancia y capaces de albergarse a los ganglios linfáticos después del trasplante, y además en donde las células son ya sea: (i) no singeneicas con tanto el sujeto como el injerto; o (ii) no singeneicas con el injerto y singeneicas con el sujeto, para de esta manera tratar al sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38071610P | 2010-09-08 | 2010-09-08 | |
PCT/IL2011/000727 WO2012032526A2 (en) | 2010-09-08 | 2011-09-08 | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013002668A MX2013002668A (es) | 2013-09-26 |
MX357746B true MX357746B (es) | 2018-07-23 |
Family
ID=45002090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013002668A MX357746B (es) | 2010-09-08 | 2011-09-08 | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9421228B2 (es) |
EP (1) | EP2613801B1 (es) |
JP (1) | JP5977238B2 (es) |
KR (1) | KR101788826B1 (es) |
CN (2) | CN105907713A (es) |
BR (1) | BR112013005756A2 (es) |
CA (1) | CA2810632C (es) |
ES (1) | ES2589678T3 (es) |
HU (1) | HUE031063T2 (es) |
IL (1) | IL225102A (es) |
MX (1) | MX357746B (es) |
PL (1) | PL2613801T3 (es) |
PT (1) | PT2613801T (es) |
SG (1) | SG188473A1 (es) |
WO (1) | WO2012032526A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2365823B1 (en) | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
PT2613801T (pt) | 2010-09-08 | 2016-09-12 | Yeda Res & Dev | Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma |
GB2500161B (en) | 2011-01-10 | 2018-12-26 | Univ Leland Stanford Junior | Enhancement of allogeneic hematopoietic stem cell transplantation |
AU2012305931B2 (en) * | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
JP6142142B2 (ja) * | 2012-04-10 | 2017-06-07 | 株式会社リンフォテック | メモリーt細胞を主成分とするリンパ球細胞群の製造方法 |
CN114457039A (zh) * | 2015-07-16 | 2022-05-10 | 耶达研究及发展有限公司 | 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途 |
JP7334043B2 (ja) | 2016-06-27 | 2023-08-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | メモリーt細胞から作られるベト細胞 |
EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
AU2018234827B2 (en) * | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
EP4055146A4 (en) * | 2019-11-05 | 2023-10-18 | Yeda Research and Development Co. Ltd | USE OF VETO CELLS TO TREAT T-CELL-MEDIATED AUTOIMMUNE DISEASES |
MX2022005418A (es) * | 2019-11-05 | 2022-08-15 | Yeda Res & Dev | Uso de celulas de veto para el tratamiento de la enfermedad de celulas falciformes. |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5599703A (en) | 1993-10-28 | 1997-02-04 | The United States Of America As Represented By The Secretary Of The Navy | In vitro amplification/expansion of CD34+ stem and progenitor cells |
US6803036B1 (en) | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
WO2000039294A1 (en) | 1998-12-24 | 2000-07-06 | Novartis Ag | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation |
US6544506B2 (en) * | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
US6759035B2 (en) | 2000-04-11 | 2004-07-06 | University Of Southen California | Method to prevent graft rejection using TGF-beta to induce T suppressor cells |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
SK287940B6 (sk) | 2000-07-03 | 2012-05-03 | Bristol-Myers Squibb Company | Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use |
EP1337152A4 (en) | 2000-11-30 | 2004-08-11 | Yeda Res & Dev | METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE |
JP4837880B2 (ja) | 2001-05-23 | 2011-12-14 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ctla4突然変異体分子を使って同種異系島移植片を保護する方法 |
US20030147859A1 (en) | 2001-06-18 | 2003-08-07 | Yair Reisner | Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance |
RU2353384C2 (ru) | 2003-08-04 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4 |
CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
PT1814580T (pt) | 2004-11-24 | 2016-11-11 | Hutchinson Fred Cancer Res | Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais |
NZ561655A (en) | 2005-04-06 | 2010-01-29 | Bristol Myers Squibb Co | Methods for treating immune disorders associated with graft transplantation with soluable CTLA4 mutant molecules |
EP2514315A3 (en) | 2005-08-24 | 2012-11-07 | Yeda Research and Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
GB0606776D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
US20110165639A1 (en) * | 2008-08-15 | 2011-07-07 | Brijen Biotech, Llc | Refinery process to produce biofuels and bioenergy products from home and municipal solid waste |
US8200915B2 (en) | 2008-08-22 | 2012-06-12 | Cadence Design Systems, Inc. | Management of very large streaming data sets for efficient writes and reads to and from persistent storage |
EP2365823B1 (en) | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
PT2613801T (pt) | 2010-09-08 | 2016-09-12 | Yeda Res & Dev | Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma |
MX2013002667A (es) | 2010-09-08 | 2013-08-01 | Yeda Res & Dev | Una combinacion de farmacos inmunosupresores para un injerto estable y a largo plazo. |
AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
-
2011
- 2011-09-08 PT PT117733253T patent/PT2613801T/pt unknown
- 2011-09-08 BR BR112013005756-4A patent/BR112013005756A2/pt not_active Application Discontinuation
- 2011-09-08 MX MX2013002668A patent/MX357746B/es active IP Right Grant
- 2011-09-08 CN CN201610307275.9A patent/CN105907713A/zh active Pending
- 2011-09-08 KR KR1020137008892A patent/KR101788826B1/ko active IP Right Grant
- 2011-09-08 CN CN201180053858.9A patent/CN103282047B/zh active Active
- 2011-09-08 US US13/821,255 patent/US9421228B2/en active Active
- 2011-09-08 WO PCT/IL2011/000727 patent/WO2012032526A2/en active Application Filing
- 2011-09-08 EP EP11773325.3A patent/EP2613801B1/en active Active
- 2011-09-08 HU HUE11773325A patent/HUE031063T2/en unknown
- 2011-09-08 PL PL11773325.3T patent/PL2613801T3/pl unknown
- 2011-09-08 SG SG2013017439A patent/SG188473A1/en unknown
- 2011-09-08 CA CA2810632A patent/CA2810632C/en active Active
- 2011-09-08 ES ES11773325.3T patent/ES2589678T3/es active Active
- 2011-09-08 JP JP2013527738A patent/JP5977238B2/ja active Active
-
2013
- 2013-03-07 IL IL225102A patent/IL225102A/en active IP Right Grant
-
2016
- 2016-08-22 US US15/242,666 patent/US20160354410A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130171108A1 (en) | 2013-07-04 |
SG188473A1 (en) | 2013-05-31 |
MX2013002668A (es) | 2013-09-26 |
BR112013005756A2 (pt) | 2018-12-26 |
CN103282047B (zh) | 2016-08-24 |
CN105907713A (zh) | 2016-08-31 |
KR20140030094A (ko) | 2014-03-11 |
PT2613801T (pt) | 2016-09-12 |
ES2589678T3 (es) | 2016-11-15 |
JP2013537187A (ja) | 2013-09-30 |
WO2012032526A2 (en) | 2012-03-15 |
EP2613801A2 (en) | 2013-07-17 |
CN103282047A (zh) | 2013-09-04 |
IL225102A (en) | 2017-05-29 |
CA2810632C (en) | 2020-06-02 |
KR101788826B1 (ko) | 2017-10-20 |
PL2613801T3 (pl) | 2016-12-30 |
WO2012032526A3 (en) | 2012-05-18 |
US9421228B2 (en) | 2016-08-23 |
EP2613801B1 (en) | 2016-06-08 |
US20160354410A1 (en) | 2016-12-08 |
JP5977238B2 (ja) | 2016-08-24 |
HUE031063T2 (en) | 2017-06-28 |
CA2810632A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX357746B (es) | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. | |
MX2021012285A (es) | Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico. | |
RU2014146170A (ru) | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации | |
NZ595331A (en) | Ex-vivo treatment of immunological disorders with pkc-theta inhibitors | |
NZ599825A (en) | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells | |
MX342995B (es) | Métodos de generar células asesinas naturales. | |
WO2012021845A3 (en) | Improved hematopoietic stem and progenitor cell therapy | |
MX339068B (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias. | |
AU2009240884A8 (en) | Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation | |
MX351226B (es) | Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades. | |
NZ701715A (en) | Means and methods for treating dlbcl | |
MX2010003019A (es) | Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia. | |
WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
WO2008030538A3 (en) | Cancer stem cell-targeted cancer therapy | |
MX2013013996A (es) | Tratamiento contra el dolor utilizando celulas madre placentarias. | |
JP2013537187A5 (es) | ||
MX2023004125A (es) | Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal. | |
EP2608797A4 (en) | CD271 PRECURSOR CELLS FROM BONE MARROW FOR CARDIAC REPAIR | |
EP2593115A4 (en) | TREATMENT OF T-CELL-MEDIATED IMMUNE TROUBLESHOOTING | |
NZ736675A (en) | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy | |
NZ595440A (en) | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds | |
MX2022005418A (es) | Uso de celulas de veto para el tratamiento de la enfermedad de celulas falciformes. | |
MX2022005416A (es) | Uso de celulas veto en el tratamiento de enfermedades autoinmune mediadas por celulas t. | |
MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |